Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan.
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan.
Microb Pathog. 2019 Jul;132:243-253. doi: 10.1016/j.micpath.2019.05.010. Epub 2019 May 7.
Ebola virus (EBOV), a non-segmented single-stranded RNA virus, is often-most transmitted through body fluids like sweat, tears, saliva, and nasal secretions. Till date, there is no licensed vaccine of EBOV is available in the market; however, the world is increasingly vulnerable to this emerging threat. Hence, it is the need of time to develop a vaccine for EBOV to hinder its dissemination. The current study has been designed for identification and characterization of the potential B and T-cell epitopes using the Immuno-informatics tools, and it helped in finding the potent vaccine candidates against EBOV. Prediction, antigenicity and allergenicity testing of predicted B and T cells' epitopes was done as well to identify their potential as a vaccine candidate and to measure their safety level respectively. Among B-cell epitopes "WIPAGIGVTGVIIA" showed a high antigenicity score and it would play an important role in evoking the immune response. In T-cell epitopes, peptides "AIGLAWIPY" and "IRGFPRCRY" presented high antigenicity score, which binds to MHC class-I and MHC class-II alleles respectively. All predicted epitopes were analyzed and compared with already reported peptides carefully. Comparatively, Peptides predicted in the present study showed more immunogenicity score than already reported peptides, used as positive control, and are more immunogenic as compared to them. Peptides reported in the present study do not target only Zaire EBOV (ZEBOV), as in previous studies, but also other species, i.e. Tai Forest EBOV (TAFV), Sudan EBOV (SUDV), Bundibugyo EBOV (BDBV), and Reston EBOV (RESTV) and would bring the promising results as potent vaccine candidates.
埃博拉病毒（EBOV）是一种非节段性单链 RNA 病毒，通常通过汗液、眼泪、唾液和鼻腔分泌物等体液传播。迄今为止，市场上尚无 EBOV 的许可疫苗；然而，世界越来越容易受到这种新出现的威胁。因此，开发一种针对 EBOV 的疫苗以阻止其传播是当务之急。本研究旨在使用免疫信息学工具鉴定和表征潜在的 B 细胞和 T 细胞表位，并寻找针对 EBOV 的有效疫苗候选物。还对预测的 B 和 T 细胞表位进行了预测、抗原性和变应原性测试，以分别确定其作为疫苗候选物的潜力和衡量其安全性水平。在 B 细胞表位中，“WIPAGIGVTGVIIA”表现出高抗原性评分，它在引发免疫反应方面将发挥重要作用。在 T 细胞表位中，肽“AIGLAWIPY”和“IRGFPRCRY”表现出高抗原性评分，分别与 MHC Ⅰ类和 MHC Ⅱ类等位基因结合。所有预测的表位都经过仔细分析和与已报道的肽进行比较。相对而言，与之前报道的用作阳性对照的肽相比，本研究中预测的肽显示出更高的免疫原性评分，并且比它们更具免疫原性。与之前的研究不同，本研究中报道的肽不仅针对扎伊尔 EBOV（ZEBOV），还针对其他物种，即泰森林 EBOV（TAFV）、苏丹 EBOV（SUDV）、邦迪布尤 EBOV（BDBV）和雷斯顿 EBOV（RESTV），并将作为有效的疫苗候选物带来有希望的结果。
